Evidence map›Paper›PMID 29781109›Full record

Trial reportClinical cardiology2018

Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.

Amanda K Verma, Jie-Lena Sun, Adrian Hernandez, John R Teerlink, Phillip J Schulte, Justin Ezekowitz, Adriaan Voors, Randall Starling, Paul Armstrong, Christopher M O'Conner and 1 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00475852 (Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00475852 phase3completednot on this map

Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)

TypeinterventionalSponsorScios, Inc.Ran2007 to 2011Enrolled7,141ConditionsHeart DecompensationArmsNesiritide, Placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Vasopressin in neonatal hypertrophic cardiomyopathy: do perceived benefits translate to clinical outcome?Journal of perinatology : official journal of the California Perinatal Association · 2021
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Amanda K VermaDepartment of Cardiology, Washington University School of Medicine, St. Louis, Missouri.ORCID http://orcid.org/0000-0001-9747-3119
Jie-Lena SunDepartment of Statistics, Duke University Medical Center, Durham, North Carolina.
Adrian HernandezDepartment of Cardiology, Duke Clinical Research Institute, Duke Hospital, Durham, North Carolina.
John R TeerlinkDepartment of Cardiology, School of Medicine, University of California, San Francisco.
Phillip J SchulteDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Justin EzekowitzDivision of Cardiology, University of Alberta, Edmonton, Canada.
Adriaan VoorsDepartment of Cardiology, University Medical Center Groningen, Groningen, the Netherlands.
Randall StarlingDepartment of Cardiology, Cleveland Clinic, Cleveland, Ohio.
Paul ArmstrongDivision of Cardiology, University of Alberta, Edmonton, Canada.
Christopher M O'ConnerDepartment of Cardiology, Duke Clinical Research Institute, Duke Hospital, Durham, North Carolina.
Robert J MentzDepartment of Cardiology, Duke Clinical Research Institute, Duke Hospital, Durham, North Carolina.
Clinical Research Institute · USUniversity of Alberta · CACleveland Clinic · USDuke University · USMayo Clinic in Florida · USUniversity Medical Center Groningen · NLUniversity of California, San Francisco · USWashington University in St. Louis · US

Funding

REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure PatientsR01AG045551 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KITZMAN, DALANE W · 2014 to 2018
$6.8M
Heart Failure Clinical Research Network Regional Clinical Center (U10)U10HL110312 · NHLBI · DUKE UNIVERSITY · PI FELKER, GARY M · 2012 to 2018
$3.5M
NHLBI NIH HHS U10 HL110312NIA NIH HHS R01 AG045551
6 · The paper itself

Abstract

backgroundHeart rate and systolic blood pressure (SBP) are prognostic markers in heart failure (HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as well as their role in heart failure with preserved ejection fraction (HFpEF) remains unclear. HYPOTHESIS: RPP and its components are associated with HFpEF outcomes.

methodsWe performed an analysis of Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF; http://www.clinicaltrials.gov NCT00475852), which studied 7141 patients with acute HF. HFpEF was defined as left ventricular ejection fraction ≥40%. Outcomes were assessed by baseline heart rate, SBP, and RPP, as well as the change of these variables using adjusted Cox models.

resultsAfter multivariable adjustment, in-hospital change but not baseline heart rate, SBP, and RPP were associated with 30-day mortality/HF hospitalization (hazard ratio [HR]: 1.17 per 5-bpm heart rate, HR: 1.20 per 10-mm Hg SBP, and HR: 1.02 per 100 bpm × mm Hg RPP; all P < 0.05). Baseline SBP was associated with 180-day mortality (HR: 0.88 per 10-mm Hg, P = 0.028). Though change in RPP was associated with 30-day mortality/HF hospitalization, the RPP baseline variable did not provide additional associative information with regard to outcomes when compared with assessment of baseline heart rate and SBP variables alone.

conclusionsAn increase in heart rate and SBP from baseline to discharge was associated with increased 30-day mortality/HF hospitalization in HFpEF patients with acute exacerbation. These findings suggest value in monitoring the trend of vital signs during HFpEF hospitalization.

Indexed as

InpatientsAgedAged, 80 and overAlbertaBlood PressureDose-Response Relationship, DrugFemaleHeart FailureHeart RateHumansMaleMiddle AgedNatriuretic AgentsNatriuretic Peptide, BrainNetherlandsPrognosisNatriuretic AgentsNatriuretic Peptide, BrainBlood Pressure Control and RegulationClinical TrialsHeart Failure

Identifiers

PMID29781109
PMCPMC6103846
OpenAlexW2803443891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.